Ascendis Pharma A/S (ASND)
NASDAQ: ASNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ASND stock chart
Technical analysisKey statistics
All statistics- Market cap
- $16.58B
- P/E (TTM)
- 16.62
- Forward P/E
- 20.47
- EPS (TTM)
- $15.21
- Dividend yield
- None
- 52-week range
- 188.08 – 282.15
- Day range
- 251.55 – 256.50
- Volume / Avg
- 602.89K / 750.65K
- Beta
- —
- Shares outstanding
- 65.60M
52-week range
ASND stock today
Shares of Ascendis Pharma A/S (ASND) finished lower on Nov 20 at $252.73, a drop of 1.26% or $3.23 per share, versus the S&P 500's 3.70% decline. At this level, ASND sits in the middle of its 52-week range of $188.08 to $282.15: 10.4% below the high, set on Jul 9, 2026 and 34.4% above the low. ASND is up 18.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.1%.
At 16.6x trailing earnings, Ascendis Pharma A/S trades below the peer-group median of 31.2x. Its forward P/E of 20.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Ascendis Pharma A/S
Company profileAscendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jan Moller Mikkelsen
- Headquarters
- Hellerup
- Employees
- 1,189
- IPO year
- 2015
- Website
- ascendispharma.com
Analyst forecast
ForecastConsensus (21 analysts)
strong_buy
Avg. price target
$315.78+24.95%
- Strong buy 5
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $1.24 vs $1.13
- Surprise
- +9.73%
ASND news
All ASND news- Ascendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Ascendis Pharma A/S Grants 28,030 Warrants to EmployeesNasdaq
- Ascendis Pharma A/S Reports Financial Results for the Period Ended September 30, 2026NasdaqASND, BF.A
- Ascendis Pharma A/S Reports Third Quarter 2026 Product Revenue of €366 millionNasdaqASND, BF.A
- Ascendis Pharma A/S Q3 Earnings Call HighlightsNasdaq
- Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call TranscriptSeeking Alpha
- TCAF, CNP, COR, ASND: ETF Outflow AlertNasdaqTCAF, CNP, COR, ASND
- Ascendis (ASND) Q3 2026 Earnings Call TranscriptNasdaq
Ascendis Pharma A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BBIOBridgeBio Pharma Inc. | 76.03 | -2.75% | $14.81B | vs ASND |
| JAZZJazz Pharmaceuticals plc | 230.26 | -2.62% | $14.78B | vs ASND |
| ALNYAlnylam Pharmaceuticals Inc. | 143.82 | -2.71% | $19.26B | vs ASND |
| ELANElanco Animal Health Incorporated | 25.74 | -2.09% | $12.87B | vs ASND |
| RDYDr. Reddy's Laboratories Ltd | 14.89 | +0.40% | $12.41B | vs ASND |
| BMRNBioMarin Pharmaceutical Inc. | 60.41 | -1.64% | $11.70B | vs ASND |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs ASND |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs ASND |
Indexes, lists and sector
Ascendis Pharma A/S stock FAQ
What is Ascendis Pharma A/S's stock price today?
ASND last traded at $252.73 as of Nov 20, 4:00 PM EST, down 1.26% on the day. Prices are delayed at least 15 minutes.
What is ASND's P/E ratio?
ASND trades at a trailing P/E ratio of 16.62 and a forward P/E of 20.47, compared with a median of 31.2 for its closest peers.
Who is Ascendis Pharma A/S's CEO?
Mr. Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S, which has about 1,189 employees.
What is the ASND 52-week high?
The 52-week high for ASND is $282.15 and the 52-week low is $188.08. The stock is currently 10.4% below its high.